New York, April 06, 2022 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Organ-on-a-Chip: Global Markets" - https://www.reportlinker.com/p05800360/?utm_source=GNW
Revenue forecasts from 2019 to 2026 are given for each type, application, offering and end user.Revenue generated from the installation and maintenance of instruments has been excluded from the report.
The application segment is characterized by various types, including drug discovery and development, toxicological research, and physiological model development, and by end-use industry, including academic and research institutes, pharmaceutical and biotechnology companies, cosmetics industry and other end users.By type market is segmented to liver, lung, kidney, heart and others.
The report also focuses on regional segmentation of the market.
Further, it explains the major drivers and regional dynamics of the global market and current trends within the industry.It also includes information about the industry structure and competitive landscape as well as the impact of COVID-19 on the market.
The report includes detailed profiles of the major players in the global organ-on-a-chip market.
Report Includes:
- 55 data tables and 29 additional tables
- An up-to-date review and analysis of the global markets for organ-on-a-chip within the biotech industry
- Analyses of the global market trends, with data from 2019 to 2021, and projections of compound annual growth rates (CAGRs) through 2026
- Information on multi-channel 3-D microfluidic cell culture chip, and discussion of their ability to imitate human microenvironment in vitro
- Evaluation and forecast the global organ-on-a-chip market size, and corresponding market share analysis by technology offering, organ type, application, end-user vertical and region
- Discussion on how organ-on-a-chip is emerging as a priority testing alternative which is replacing animals in life science research, toxicology testing and drug development studies
- Review of potential applications in pharmaceutical and life science research sectors, including preclinical drugs testing, drug screening, personalized medicine, phenotypic screening, lead optimization and disease modelling
- Insights into the recent industry structure including the government programs and policies in support of organ-on-a-chip and coverage of revised laws involving animal testing
- Review of patent grants for innovations in organ-on-a-chip technology across each major category
- Descriptive company profiles of the leading global players, including 4Dcell, BiomimX, Emulate Inc., Kirkstall Ltd., Nortis and TissUse GmbH
Summary:
An organ-on-a-chip is a type of artificial organ that possesses the capability to simulate activities, mechanics and physiological responses similar to that of an organ system.These are multi-channel 3D microfluidic cell culture chips that are primarily being used in life science and drug development research because of their ability to imitate human microenvironments in vitro.
The unique characteristics of organ-on-a-chip are worked out by integrating biology and advanced engineering. Cell biology, microfluidics and microfabrication are the core fields that have paved the way towards the development of organ-on-a-chip technology.
Organ-on-a-chip is considered to be a potential game-changing technology and is serving as a testing alternative that is replacing the use of animals in life science research, toxicology testing and drug development studies around the globe.Countries are focusing on this upcoming technology to produce safer and effective drugs.
It has been observed that pharmaceutical R&D expenses create a lot of burden on the healthcare industry because the drug discovery process requires huge investment but has a low success rate. Studies have indicated that using organ-on-a-chips for drug discovery and development studies will help to reduce the cost by 26% because many ineffective and toxic drugs can be eliminated
at the preclinical stage before they enter human trials. Also, rising demand for personalized medicines is also a contributing factor to growth in the organ-on-a-chip market. There are many diseases that still do not have any approved therapies for cures and depend only on symptomatic management, e.g., amyotrophic lateral sclerosis, cirrhosis, etc. Therefore, organ-on-a-chip will be beneficial for such indications. More research and the increasing prevalence of cancer as well as neurogenerativediseases such as Alzheimer’s, Parkinson’s disease and other rare indications will also be contributing factors for the market.
The global market for organ-on-a-chip is estimated to be REDACTED in 2020 and is expected to increase to REDACTED by 2026, growing at a CAGR of REDACTED. The organ-on-a-chip market is segmented based on type, application, end user, offering and region.
The North American region has the highest share of the organ-on-a-chip market, followed by Europe.This is because of the extensive research and developmental activities taking place in the region as well as the presence of major players, funding and the increasing prevalence of chronic diseases.
All these factors contribute to growth in the organ-on-a-chipmarket.
It has been observed that the COVID-19 pandemichad a positive impact on the organ-on-a-chip market.This is because, due to the pandemic, many institutions across the world began research projects aimed at gaining an understanding of disease pathology and developing treatment options for coronavirus.
Finally, it has also been observed that companies are now moving from single organ on a chip to multiple organ on a chip to gain a better understanding of the toxicological impact of a drug.
Read the full report: https://www.reportlinker.com/p05800360/?utm_source=GNW
About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
__________________________
